Inovio Pharmaceuticals, Inc. · NASDAQ:INO
Inovio Pharmaceuticals — World Federation of Hemophilia World Congress 2026
13 slides from Inovio Pharmaceuticals's conference presentation, Apr 22, 2026
Slide 1: Next-Gen Protein Replacement Therapeutics: DPROT Technology Demonstrates In Vivo Production of Functional HuFVIII
Next-Gen Protein Replacement Therapeutics: DNA-Encoded Protein (DPROT) Technology Demonstrates In Vivo Production of Functional HuFVIII in Mouse Model World Federation of Hemophilia April 22nd, 2026 Dr. Mike Sumner, Chief Medical Officer & Head of Development
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes statements that are, or may be deemed, “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this presentation regarding o
Slide 3: DNA Medicines: Customized In Vivo-Generated Proteins
DNA Medicines: Customized In Vivo-Generated Proteins TARGET BIOENGINEERING & PRECISELY PROPRIETARY MECHANISM OF ACTION SELECTION GENE SEQUENCING DESIGNED DEVICES PLASMIDS Skeletal Muscle Cell Selected gene Antigen-specific cytotoxic T cells to treat disease Binding/neutralizing antibodies and T cell
Slide 4: INOVIO Pipeline
INOVIO Pipeline PARTNERS/FUNDERS/ INOVIO PRODUCT PROGRAM/MODALITY INDICATION PHASE 1 PHASE 2 PHASE 3 REGISTRATIONAL COLLABORATORS RIGHTS HPV-TARGETED INO-3107 (HPV 6/11) Recurrent Respiratory Papillomatosis* Worldwide VGX-3100 (HPV 16/18) Cervical Dysplasia (HSIL) – China Ex-China VGX-3100 Anal Dysp
Slide 5: INOVIO's DNA Medicine DPROT/DMAb Platform
INOVIO’s DNA Medicine DPROT/DMAb* Platform • Targeted localized delivery utilizing CELLECTRA® device technology CELLECTRA® 5PSP - Without need for lipid nanoparticles or viral vectors • Platform supported by comprehensive nonclinical GLP toxicology and biodistribution studies - These studies support
Slide 6: Next-Generation Platform: Proof-of-Concept Clinical Data
Next-Generation Platform Proof-of-Concept Clinical Data
Slide 7: Next-Generation DNA Medicine – Clinical Proof-of-Concept
Next-Generation DNA Medicine – Clinical Proof-of-Concept • DARPA funded, Wistar Institute-led proof-of-concept Phase 1 clinical trial in collaboration with AstraZeneca, the University of Pennsylvania and INOVIO to develop anti-SARS-CoV-2-specific DMAbs - Data highlight potential to deliver a broad s
Slide 8: Ongoing Phase Trial with DMAbs
Ongoing Phase 1 Trial with DMAbs • Long-lasting in vivo antibody production: DMAb 2048 levels remained stable for 96 weeks in all participants Serum Concentration, ng/mL reaching that timepoint 1024 512 • No anti-drug antibodies (ADA): no immune rejection of the DMAbs detected across ~1,000 blood sa
Slide 9: Tolerability Profile of DMAb Administered with CELLECTRA IM
Tolerability Profile of DMAb Administered with CELLECTRA® IM • Elicited AEs (≤7 days post-dose): Frequency and severity of treatment- or procedure-related elicited AEs are shown - Very low frequency of systemic AE's versus other delivery platforms • Pain Assessment: Pain perception is highly variabl
Slide 10: DPROT: An Alternative to Viral-based Delivery for Long-Term In Vivo Protein Expression
DPROT: An Alternative to Viral-based Delivery for Long-Term In Vivo Protein Expression • Sustained in vivo protein expression remains a crucial objective in the treatment of genetic disorders such as hemophilia • Despite notable progress, several challenges persist: - Pre-existing immunity to viral
Slide 11: INOVIO DPROT Approach for Hemophilia A: HuFVIII Expressed and Functional in FVIII KO Mice
INOVIO DPROT Approach for Hemophilia A: Human FVIII (HuFVIII) is Expressed and Functional in FVIII KO Mice Mouse tail clip model HuFVIII Activity Confirms complex proteins such 0.7 as huFVIII can be effectively Activity (mean ± SEM) 0.6 Human FVIII (IU/ml) 0.5 produced, assembled in 0.4 myocytes and
Slide 12: DMAb/DPROT: Potential New Therapeutic Paradigm
DMAb/DPROT: Potential New Therapeutic Paradigm • Platform has demonstrated ability to achieve long-term protein expression and secretion - Clinical PoC published in Nature Medicine1 - Serum levels within therapeutic range for multiple diseases; we expect platform optimization to enable higher serum
Slide 13: Thank you.
Thank you. michael.sumner@inovio.com
INOVIO Pharmaceuticals — World Federation of Hemophilia World Congress 2026 on 6ix